How can we measure the value of #genomics in #healthcare? How can #HTA, #implementation & data management be adapted to suit the rapidly evolving nature of genomics? For insights, read the Review from Zornitza Stark, Ilias Goranitis & colleagues. https://www.nature.com/articles/s41591-025-04061-3

In this Nature Medicine paper, we draw from our experiences in evaluating and implementing #genomics in Australia, Canada, England, Hong Kong and the US www.nature.com/articles/s41...

Determining the value of genomics in healthcare” is now published in Nature Medicine. Led by A/Prof Ilias Goranitis, the paper brings together international co-authors to examine how the value of genomics can be assessed. Read the full article: www.nature.com/articles/s41...

www.nature.com/articles/s41... 🔥🔥🔥 Is genomics value for money??? 🧬💰 👉 How do we define it? 👉 Measure it? 👉 And deliver it? rdcu.be/eR243 @iliasgoranitis.bsky.social @stephaniebest.bsky.social @hadleyssmith.bsky.social @rich-genomics.bsky.social @jbuchanan-ox.bsky.social @rdexeter.bsky.social

Proud to share our BabyScreen+ #gNBS study is now out in @naturemedicine.bsky.social: 1000 babies screened, results in <2wks, 16 high chance findings, incl. 2 with major impact on care. Big thanks to @zornitza.bsky.social and the study team! www.nature.com/articles/s41...

🤗 Out now @naturemedicine.bsky.social results of our genomic NBS study BabyScreen+ 👶🧬 👉 www.nature.com/articles/s41... 1,000 babies WGS using existing cards 600+ conditions 13 day TAT 16 diagnoses (vs 1 in std NBS) High clinical impact High parental acceptability

Help us develop a roadmap for stakeholders to consider when integrating #healtheconomics alongside #genomics to inform decision-making. Please share your local perspectives on challenges & opportunities of evaluating and implementing genomics q.surveys.unimelb.edu.au/jfe/form/SV_...

Wonderful to see our paper on the #Value and #Implementation of #Genomic_Newborn_Screening published in @ajhgnews.bsky.social #BabyScreen+ #HealthEconomics #DCE

What does the Australian public think about the value and implementation of genomic NBS? 🧬👶⚖️ @ajhgnews.bsky.social @iliasgoranitis.bsky.social @stephaniebest.bsky.social @genomeseb.bsky.social @genetic-fi.bsky.social #raredisease #genomics #healtheconomics www.sciencedirect.com/science/arti...

A few weeks ago, @iliasgoranitis.bsky.social presented at the Pan American Health Organisation webinar series. The webinar explored the challenges and opportunities of incorporating genomic innovations into health systems. youtube.com/watch?v=cPQr...

A must-read: The Cost-Effectiveness of #Genomic_Medicine in #Cancer Control: A Systematic Literature Review link.springer.com/article/10.1... Grateful to the @who.int and Cancer Australia for their support.

As @ausgenomics.bsky.social comes to an end: what have we learned? 🇦🇺🧬 @naturemedicine.bsky.social 👉 rdcu.be/eeuAN Change is hard! Key for success: working across disciplines; jurisdictions; and all leadership levels🏆 @stephaniebest.bsky.social @iliasgoranitis.bsky.social @andrewmallett8.bsky.social

(1/4) Attention Early Career Researchers (ECRs)! We are still collecting expressions of interest for our ECR ‘Preprint Club’ series for 2025. #IHEA #healtheconomics #genomics #precisionmedicine

What happens when #genomic testing is funded?🧬 👉 rdcu.be/d8MSL Last 10yrs 🇦🇺: Many tests approved as evidence grows ✅ BUT testing volumes low AND inequitable access Budget impact of #genomics minor: AU$3Mpa or <0.01% of all health expenditure 💰 @ausgenomics.bsky.social @iliasgoranitis.bsky.social

New paper in the European Journal of Human Genetics: Utilisation of subsidised genetic and genomic testing in Australia during 2014–2023 www.nature.com/articles/s41...

@CancerAustralia has now launched the National Framework for Genomics in Cancer Control. www.canceraustralia.gov.au/key-initiati... It was an honor to lead the #healtheconomics component of the evidence review that informed the development of this framework. Access it through link ⬇️

How do we measure the value of #genomics for #policy decisions? Check out our new GUV scale! 👉 www.valueinhealthjournal.com/article/S109... 👏 great collaboration @iliasgoranitis.bsky.social @andrewmallett8.bsky.social @stephaniebest.bsky.social @zoefehlberg.bsky.social @ausgenomics.bsky.social

GUV-scale New way to measure & score genomic utility on a 0-100% scale based on 5 policy priority indicators (clinical, diagnostic, economic, societal, and family utility) doi.org/10.1016/j.jv... @zornitza.bsky.social @stephaniebest.bsky.social @andrewmallett8.bsky.social @ausgenomics.bsky.social

New role within our Economics of Genomics & Precision Medicine Unit - Applications deadline Jan 20 #healtheconomics jobs.unimelb.edu.au/caw/en/job/9...

Honoured to receive a Dame Kate Campbell Fellowship and join excellent colleagues in the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne who have inspired me with their work over the years!

An important step towards the economic evaluation of #FunctionalGenomics! A #MicroCosting of mass-spectrometry based quantitative #Proteomics url.au.m.mimecastprotect.com/s/TeIxCxnMJ5... @ausgenomics.bsky.social

Economics of Genomics and Precision Medicine Unit Strategy Day reflections and fun - So proud of the personal & professional qualities of my team #HealthEconomics #Genomics

On Friday the Australian Government made an important announcement about the new #GenomicsAustralia, a national body that will provide leadership, coordination and expertise so all Australians can reap the benefits of cutting-edge genomic research and technologies. www.health.gov.au/ministers/th...

Meet our team! @jbuchanan-ox.bsky.social, Ilias Goranitis, and Deirdre Weymann are the founders and lead conveners of the International Health Economics Association Genomics & Precision Medicine Special Interest Group (i.e., the #IHEA Econ-Omics SIG). #healtheconomics #genomics #precisionmedicine